Arbutus Biopharma
ABUS
62 hedge funds and large institutions have $44M invested in Arbutus Biopharma in 2019 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 17 reducing their positions, and 25 closing their positions.
6% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 17
5.82% less ownership
Funds ownership: 42.96% → 37.14% (-5.8%)
14% less funds holding
Funds holding: 72 → 62 (-10)
28% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 25
49% less call options, than puts
Call options by funds: $25K | Put options by funds: $49K
49% less capital invested
Capital invested by funds: $86.5M → $44M (-$42.5M)
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$1.65M |
| 2 |
Jennison Associates
New York
|
+$1.61M |
| 3 |
Millennium Management
New York
|
+$1.33M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.28M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$601K |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$7.78M |
| 2 |
BlackRock
New York
|
-$4.23M |
| 3 |
State Street
Boston,
Massachusetts
|
-$1.36M |
| 4 |
JP Morgan Chase
New York
|
-$1.21M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$884K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
William Blair & Company
Chicago,
Illinois
| – | -$45K | -12,700 | Closed |
|
|
SO
77
STRS Ohio
Columbus,
Ohio
| – | -$36K | -10,300 | Closed |
|
|
JG
78
Jefferies Group
New York
| – | -$36K | -10,187 | Closed |
|
|
CG
79
Cutler Group
San Francisco,
California
| – | -$12K | -3,600 | Closed |
|
|
SIAP
80
Sterling Investment Advisors (Pennsylvania)
Berwyn,
Pennsylvania
| – | -$11K | -3,000 | Closed |
|
|
AIP
81
Ameritas Investment Partners
Lincoln,
Nebraska
| – | -$11K | -2,944 | Closed |
|
|
NFG
82
Next Financial Group
Houston,
Texas
| – | -$1K | -200 | Closed |
|
ABUS Hedge Fund Activity: Q2 2019 in Review
62 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q2 2019, worth a combined $44M — down 49% from $86.5M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ABUS and 18 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 16 added.
The largest buyer was Morgan Stanley, adding an estimated $1.65M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $7.78M sold.
- 62 institutional investors held Arbutus Biopharma (ABUS) as of Q2 2019, down from 72 in Q1 2019.
- Funds reported $44M of Arbutus Biopharma stock for Q2 2019, down 49% quarter-over-quarter.
- 18 funds opened new Arbutus Biopharma positions in Q2 2019 and 25 closed out, a net change of -7 holders.
- The largest Arbutus Biopharma buyer in Q2 2019 was Morgan Stanley, an estimated $1.65M added.
- The largest Arbutus Biopharma seller in Q2 2019 was EcoR1 Capital, an estimated $7.78M sold.
Based on aggregated 13F filings for Q2 2019.